Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
2(50.0%)
Phase 1
2(50.0%)
4Total
Early Phase 1(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05105867Early Phase 1Unknown

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Role: collaborator

NCT05570188Phase 1Withdrawn

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

Role: lead

NCT05507996Early Phase 1Terminated

Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome

Role: lead

NCT05571540Phase 1Withdrawn

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

Role: lead

All 4 trials loaded